‪Douglas Lorne Arnold, MD, FRCP(C)‬

Cited by

	All	Since 2020
Citations	61640	21740
h-index	127	66
i10-index	417	282

4400

2200

1100

3300

19911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025163 145 184 225 308 291 454 525 716 828 1078 1135 1076 1173 1356 1234 1278 1347 1330 1405 1380 1702 1984 2216 2384 2705 3105 3150 3490 3653 4319 4324 4200 4221 964

Public access

View all

99 articles

29 articles

available

not available

Based on funding mandates

Co-authors

Amit Bar-OrProfessor, University of PennsylvaniaVerified email at pennmedicine.upenn.edu
Sridar Narayanan, PhDAssistant Professor: Department of Neurology and Neurosurgery, McGill UniversityVerified email at mcgill.ca
Paul M. MatthewsEdmond and Lily Safra Chair, Professor of Clinical Neurosciences, Imperial College LondonVerified email at imperial.ac.uk
D. Louis CollinsProfessor of Biomedical Engineering and Neurology & Neurosurgery, McGill UniversityVerified email at mcgill.ca
Nicola De StefanoProfessor of Neurology, Universtiy of Siena,Verified email at unisi.it
Gavin GiovannoniQueen Mary University of LondonVerified email at giovannoni.net
Jerry S Wolinsky, MDEmeritus Professor in Neurology, McGovern Medical School, UTHealth, The University of Texas HealthVerified email at uth.tmc.edu
Zografos CaramanosMcConnell Brain Imaging Centre, Montreal Neurological Institute, McGill UniversityVerified email at mcgill.ca
Fernando CendesFull Professor, Department of Neurology, FCM, University of Campinas - UNICAMP, BrazilVerified email at unicamp.br
Jeffrey A CohenCleveland ClinicVerified email at ccf.org
Robert J FoxMellen Center for Multiple Sclerosis, Cleveland ClinicVerified email at ccf.org
eric shoubridgeProfessor, Human Genetics, McGill UniversityVerified email at ericpc.mni.mcgill.ca
Li Min LiProfessor of Neurology, Faculty of Medical Sciences at University of CampinasVerified email at fcm.unicamp.br
Robert A BrownUniversity of Calgary; Montreal Neurological Institute; ShadowLab Research Inc.Verified email at shadowlabresearch.com
Bruce PikeCAIP Chair in Healthy Brain Aging, Head of Image Science, Professor - U of CalgaryVerified email at ucalgary.ca
John G. SledSenior Scientist, Hospital for Sick Children / Professor, University of TorontoVerified email at utoronto.ca
Emmanuelle WaubantProfessor of Neurology and PediatricsVerified email at ucsf.edu
Colm ElliottNeuroRx ResearchVerified email at neurorx.com
Alasdair ColesUniversity of CambridgeVerified email at medschl.cam.ac.uk
Tal ArbelProfessor of Electrical & Computer Engineering, McGill UniversityVerified email at cim.mcgill.ca

Douglas Lorne Arnold, MD, FRCP(C)

James McGill Professor: Department of Neurology and Neurosurgery, Faculty of Medicine, McGill

Verified email at mcgill.ca - Homepage

Magnetic Resonance Imaging Neurological Disorders Multiple Sclerosis Alzheimer's Disease


Title Sort by citations Sort by year Sort by title	Cited by Cited by	Year
B-cell depletion with rituximab in relapsing–remitting multiple sclerosis SL Hauser, E Waubant, DL Arnold, T Vollmer, J Antel, RJ Fox, A Bar-Or, ... New England Journal of Medicine 358 (7), 676-688, 2008	2874	2008
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis X Montalban, SL Hauser, L Kappos, DL Arnold, A Bar-Or, G Comi, ... N Engl J Med 376 (3), 209-220, 2017	2150	2017
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis R Gold, L Kappos, DL Arnold, A Bar-Or, G Giovannoni, K Selmaj, ... New England Journal of Medicine 367 (12), 1098-1107, 2012	2143	2012
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis SL Hauser, A Bar-Or, G Comi, G Giovannoni, HP Hartung, B Hemmer, ... N Engl J Med 376 (3), 221-234, 2017	2076	2017
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial JA Cohen, AJ Coles, DL Arnold, C Confavreux, EJ Fox, HP Hartung, ... The Lancet 380 (9856), 1819-1828, 2012	1331	2012
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial AJ Coles, CL Twyman, DL Arnold, JA Cohen, C Confavreux, EJ Fox, ... The lancet 380 (9856), 1829-1839, 2012	1310	2012
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P ... Lancet 391 (10127), 1263-1273, 2018	1091	2018
Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability N De Stefano, S Narayanan, GS Francis, R Arnaoutelis, MC Tartaglia, ... Archives of neurology 58 (1), 65-70, 2001	687	2001
Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy MC Preul, Z Caramanos, DL Collins, JG Villemure, R Leblanc, A Olivier, ... Nature medicine 2 (3), 1996	687	1996
Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis: Results of a longitudinal magnetic resonance spectroscopy study N De Stefano, PM Matthews, L Fu, S Narayanan, J Stanley, GS Francis, ... Brain 121 (Pt 8), 1469-1477, 1998	631	1998
Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial A Bar‐Or, PAJ Calabresi, D Arnold, C Markowitz, S Shafer, LH Kasper, ... Annals of neurology 63 (3), 395-400, 2008	621	2008
Imaging axonal damage of normal-appearing white matter in multiple sclerosis L Fu, PM Matthews, N De Stefano, KJ Worsley, S Narayanan, GS Francis, ... Brain 121 (1), 103-113, 1998	609	1998
Mesial temporal damage in temporal lobe epilepsy: a volumetric MRI study of the hippocampus, amygdala and parahippocampal region N Bernasconi, A Bernasconi, Z Caramanos, SB Antel, F Andermann, ... Brain 126 (2), 462-469, 2003	594	2003
Metabolic recovery after exercise and the assessment of mitochondrial function in vivo in human skeletal muscle by means of 31P NMR DL Arnold, PM Matthews, GK Radda Magnetic resonance in medicine 1 (3), 307-315, 1984	581	1984
Reversible decreases in N‐acetylaspartate after acute brain injury ND Stefano, PM Matthews, DL Arnold Magnetic Resonance in Medicine 34 (5), 721-727, 1995	539	1995
Exploring uncertainty measures in deep networks for Multiple sclerosis lesion detection and segmentation AT Nair T, Precup D, Arnold DL Med Image Anal 59, 101557, 2020	531	2020
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled … Kappos L, Wolinsky JS, Giovannoni G, Arnold DL, Wang Q, Bernasconi C, Model ... JAMA Neurol [PMID: 32511687; Epub: 2020/06/09] 77 (9), 1132-1140, 2020	485*	2020
Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study PA Calabresi, BC Kieseier, DL Arnold, LJ Balcer, A Boyko, J Pelletier, ... The Lancet Neurology 13 (7), 657-665, 2014	479	2014
Review of automatic segmentation methods of multiple sclerosis white matter lesions on conventional magnetic resonance imaging D Garcia-Lorenzo, S Francis, S Narayanan, DL Arnold, DL Collins Medical image analysis 17 (1), 1-18, 2013	465	2013
Incidence of acquired demyelination of the CNS in Canadian children B Banwell, J Kennedy, D Sadovnick, DL Arnold, S Magalhaes, ... Neurology 72 (3), 232-239, 2009	432	2009

The system can't perform the operation now. Try again later.

Articles 1–20

Citations per year

Duplicate citations

Merged citations

Add co-authorsCo-authors

Follow

Cited by

Co-authors